Researchers recently sought to evaluate the efficacy and safety of infliximab biosimilar CT-P13 in the treatment of Takayasu arteritis (TAK), a granulomatous inflammatory vasculitis that affects the aorta and can cause aneurysms to form. Some patients with TAK benefit from corticosteroids or second-line, small-molecule immunosuppressive agents, but there is a demand for more effective therapeutic options.
Researchers recently sought to evaluate the efficacy and safety of infliximab biosimilar CT-P13 in the treatment of Takayasu arteritis (TAK), a granulomatous inflammatory vasculitis that affects the aorta and can cause aneurysms to form. Some patients with TAK benefit from corticosteroids or second-line, small-molecule immunosuppressive agents, but there is a demand for more effective therapeutic options.
Investigators designed a single-center, prospective, open-label study that enrolled 12 patients with TAK who received the infliximab biosimilar. One patient was excluded for analysis due to a protocol violation. All participants were female with a mean age of 46.8 years. The trial enrolled patients who had taken a daily dose of 10 mg of prednisolone (or its equivalent), and the dose was maintained for at least 2 weeks prior to the initiation of treatment with CT-P13 and throughout the study.
Patients received intravenous infusions of biosimilar infliximab at a starting dose of 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks up to week 46. Patients whose erythrocyte sedimentation rate (ESR) had not improved by 50% or more at week 14 were required to increase the dose of CT-P13 by 1.5 mg/kg. Patients were followed to week 54.
The primary endpoint was the achievement of either partial or complete remission by week 30, and secondary endpoints included changes in modified Indian Takayasu Clinical Activity Score (ITAS-A) and serum levels of acute phase reactants at week 30 from baseline.
At week 30, 3 (27.3%) of the 11 patients treated with CT-P13 achieved complete remission, while 6 (54.5%) patients achieved partial remission. Researchers noted that the therapy failed in 2 patients.
Both sustained clinical and serologic response was seen in 4 (44.4%) of the patients who initially achieved either complete or partial remission. The other 3 patients (33.3%) included in the study maintained clinical response but had abnormalities of acute phase reactants, wrote the study authors.
The researchers found that, during the treatment period, no adverse events (AEs) or serious AEs occurred that would call for a discontinuation of treatment. In general, minor infection events were the most frequently reported adverse event, including upper respiratory tract infection and viral keratitis.
Though the trial had a relatively small number of patients, and no definitive conclusions could be drawn regarding the efficacy of infliximab for the treatment of TAK, the researchers said that the findings set a basis for future studies. “This prospective open-label trial of…CT-P13 suggests that CT-P13 therapy may lead to remission or improvement with lower glucocorticoid requirement in TAK. Randomized controlled studies are warranted to assess the long-term efficacy and safety of infliximab and propose precise treatment guidelines for infliximab in TAK,” wrote the investigators.
Reference
Hye Park E, Young Lee E, Jong Lee Y, et al. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int. 2018; 38(12): 2233-2242. ncbi.nlm.nih.gov/pmc/articles/PMC6223861/. Accessed January 17, 2018.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.